Immunai Stock
HealthTechLooking to sell Immunai stock or options?
Immunai is a bioinformatics platform designed to improve our understanding of complex diseases and facilitate more effective targeted therapy development. By leveraging artificial intelligence, the platform analyzes extensive biological datasets and forecasts treatment outcomes, which empowers healthcare researchers to enhance drug discovery and development processes.
Meron Capital, Endless Frontier Labs, 8VC, Alexandria Venture Investments, Gefen Capital, Perot Jain, Dexcel Pharma, Piedmont Capital Investments, Talos Ventures, Duquesne Family Office, iAngels, TLV Partners, Schusterman Family Investments, ICON (Palo Alto), R-Squared Ventures, Koch Disruptive Technologies, Gad Allon, Piedmont, MIT Startup Exchange, Viola Ventures, AI Venture Labs, Catalio Capital Management.